

Join Prof. Boesen, IAG’s Sn Theraputic Area Lead and Collaborators to Discuss the Role of AI in Imaging
Renowned A.I. expert, Prof. Mikael Boesen, MD, PhD, addressed the OARSI community and drug development companies in a recent webinar on the Role of Artificial Intelligence in Imaging.
The webinar, titled “Role of Artificial Intelligence in Imaging: Implications for Drug Development,” took place on Wednesday, May 15, 2024, from 8:00 to 9:00 am ET. This event served as a platform for scientists and industry leaders to explore the transformative potential of AI in medical imaging within the context of drug development.
Prof. Boesen, currently Professor of MSK Radiology & AI and Co-Founder of RAIT.dk and CLIC-project.org, offered strategic perspectives and actionable insights to empower drug development experts in navigating the evolving landscape of AI in medical imaging1.
The webinar covered key topics including:
-
The role of AI in streamlining imaging processes in drug development
-
Leveraging AI-powered image analysis for enhanced efficacy and safety assessments in clinical trials
-
Strategies for integrating AI technologies into existing workflows
-
Regulatory considerations and best practices for deploying AI solutions in drug development settings
For those who missed the live event, the recorded webinar is now available for viewing. Chief Medical Officers, medical directors, and other senior executives involved in drug development and clinical research can access the recording and follow up with Prof. Boesen by emailing their questions to imaging.experts@ia-grp.com.
To register and view the recorded webinar, please visit: https://oarsi.org/education/oarsi-live-webinar-series
This webinar was organized by Image Analysis Group (IAG), a leading imaging Clinical Research Organization that combines medical and operational expertise with cutting-edge proprietary A.I. capabilities to power drug development. IAG has been serving biotech and pharma clients globally since 2007, supporting all aspects of phase I to III imaging trials across multiple indications.